In 2023, the U.S. FDA approved 55 new drugs, 17 of which were biopharmaceuticals. Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, contributed to four, which equals nearly 25% of these biopharmaceuticals.
 
Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, commented: “Guiding a promising therapy from its initial clinical trials to commercialization is a demanding endeavor that spans numerous years of development efforts. We provide clients with world-class solutions along the entire biopharmaceutical value chain from bioprocess development to manufacturing and regulatory support. These recent approvals illustrate our capability to support our client partners through this entire and challenging process, emphasizing the importance of our expertise and flexibility to match unique client needs.”
 
Currently, Rentschler Biopharma is manufacturing a total of eight market approved biopharmaceuticals for its clients, including complex formats such as bispecific antibodies, as well as recombinant enzymes. Rentschler Biopharma’s involvement in bringing these therapeutics to the market underpins the company’s strategic role in developing innovative treatments for cancer, autoimmune disorders, as well as rare diseases.
 
For the four newly approved products, Rentschler Biopharma provided support with integrated capabilities, including consulting, regulatory services, process development, technology transfer and manufacturing. These collaborations involved international clients, showcasing the company’s global reach and excellence across its manufacturing sites.
 
Benedikt von Braunmühl, CEO of Rentschler Biopharma, said: “I am very grateful and proud that our company continuously makes important contributions in the development and manufacturing of innovative biopharmaceuticals and in realizing our clients’ ideas. My sincere gratitude goes to our cross-site teams for their integral contributions to this significant milestone and for their dedication, which is reflected in every aspect of our work.”

More Rentschler Biopharma News